Ron Cohen, Acorda
Struggling Acorda team brings out the axe — yet again — to chop away at costs as sales sputter
With its market value mired deep in the cellar of microcap stocks and its franchise drug struggling to gain traction, Acorda CEO Ron Cohen is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
